Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322756 | 1.00 | MMP13 (0.34) | MMP13AAK1ADAM17MEN1KMT2A | |
| SCHEMBL7099544 | 0.81 | PDK2 (0.33) | MMP13MEN1KMT2A | |
| SCHEMBL7098975 | 0.81 | CHRNB2 (0.33) | MMP13AAK1 | |
| SCHEMBL6458723 | 0.79 | CA2 (0.38) | MMP13AAK1 | |
| SCHEMBL7550965 | 0.78 | PIN1 (0.40) | AAK1 | |
| SCHEMBL3325125 | 0.78 | CHRNB2 (0.49) | MEN1KMT2A | |
| SCHEMBL7550970 | 0.78 | PIN1 (0.40) | AAK1 | |
| SCHEMBL7553195 | 0.78 | PIN1 (0.40) | AAK1 | |
| SCHEMBL3325118 | 0.78 | CHRNB2 (0.49) | MEN1KMT2A | |
| SCHEMBL7529058 | 0.75 | SYK (0.40) | MMP13AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-12-28 | — | — | US | disclosed |
| US-7045538-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | DULL GARY MAURICE (US) | 2003-05-08 | — | — | US | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CHRM3, CHRM5, CHRM4 | MMP13 4060/4885AAK1 3613/4885ADAM17 3791/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | MMP13 3712/4885AAK1 3270/4885ADAM17 4125/4885 |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, HTR3E | MMP13 1201/4885AAK1 4411/4885ADAM17 3448/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | MMP13 4060/4885AAK1 3613/4885ADAM17 3791/4885 |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRM3, CHRM5, CHRM4 | MMP13 4060/4885AAK1 3613/4885ADAM17 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.